Condition: Metastatic Breast Cancer · ER Positive Breast Cancer · HER2-negative Breast Cancer · Sponsor: Fondazione Sandro Pitigliani
This is a multi-center biomarkers study aiming to prospectively collect biological samples from patients with ER+ and HER2-negative metastatic breast cancer, who are candidate to first-line treatment with an aromatase inhibitor and a CDK4/6 inhibitor as per standard clinical practice. Blood and tissue samples will be collected for biomarker analysis, including thymidine kinase1 activity, gene expression signatures and circulating tumor DNA.
This description comes directly from the study's public registry record.
Luca Malorni · +390574802523 · luca.malorni@uslcentro.toscana.it
Chiara Biagioni · +390574802526 · chiara.biagioni@uslcentro.toscana.it
Always discuss trial participation with your own doctor first.
| Hospital Santo Stefano | Prato, Tuscany, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04660435